ASX-listed PharmAust Limited has delivered the final report on its successful Phase II clinical trial, using the Monepantel drug to treat cancer in dogs, to the US$8.8B market capped pharmaceutical giant, NYSE-listed Elanco. Under an option agreement inked two years ago with PharmAust, the animal health-focused mega-Pharma company now has six months to take up the option to licence, manufacture, and market Monepantel globally.
15/07/2020 - 13:44
PharmAust chases global licencing for canine cancer drug
By Matt Birney
15/07/2020 - 13:44
Related Data & Insights
-
-
Rank Company Revenue 128th PharmAust $3.8m 137th Adisyn $2.9m 138th rent.com.au $2.8m 141st Douugh $2.5m 142nd Hazer Group $2.4m 202 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Related Articles
24 Apr 2024
Board Moves, April 24 2024
23 Apr 2024
PharmAust CEO resigns
05 Feb 2024
Board Moves February 5, 2024
28 Aug 2023
Board Moves August 28, 2023
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX